You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxiconazole
Accession NumberDB00239  (APRD01154)
TypeSmall Molecule
GroupsApproved
DescriptionOxiconazole nitrate (U.S.: Oxistat, Canada: Oxizole) is an antifungal medication typically administered in a cream or lotion to treat skin infections such as athlete's foot, jock itch and ringworm. [Wikipedia]
Structure
Thumb
Synonyms
Oxiconazol
Oxiconazole
Oxiconazolum
External Identifiers
  • Ro 13-8996
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxiconazole NitrateCream10 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2016-03-09Not applicableUs
OxistatCream10 mg/gTopicalPharma Derm, A Division Of Nycomed Us Inc.2006-01-25Not applicableUs
OxistatCream10 mg/gTopicalPharma Derm A Division Of Fougera Pharmaceuticals Inc.1988-12-30Not applicableUs
OxistatLotion10 mg/gTopicalPharma Derm, A Division Of Nycomed Us Inc.2006-01-25Not applicableUs
OxistatLotion10 mg/mLTopicalPharma Derm A Division Of Fougera Pharmaceuticals Inc.1992-09-30Not applicableUs
OxistatLotion30 mg/gTopicalRebel Distributors Corp.2006-01-25Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxiconazole NitrateCream10 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2016-03-07Not applicableUs
Oxiconazole Nitrate Cream 1%Cream10 mg/gTopicalWelgo, Llc2016-08-01Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OxizoleCream1 %TopicalValeo Pharma Inc1998-05-212006-07-31Canada
OxizoleLotion10 mgTopicalStiefel Canada Ulc1998-05-212002-04-02Canada
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxiconazole nitrate
64211-46-7
Thumb
  • InChI Key: WVNOAGNOIPTWPT-NDUABGMUSA-N
  • Monoisotopic Mass: 489.9769157
  • Average Mass: 492.13
DBSALT000892
Categories
UNIIC668Q9I33J
CAS number64211-45-6
WeightAverage: 429.12
Monoisotopic: 426.9812729
Chemical FormulaC18H13Cl4N3O
InChI KeyQRJJEGAJXVEBNE-HKOYGPOVSA-N
InChI
InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+
IUPAC Name
(Z)-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethylidene][(2,4-dichlorophenyl)methoxy]amine
SMILES
ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
Pharmacology
IndicationFor treatment of dermal fungal infection.
Structured Indications
PharmacodynamicsOxiconazole is a broad-spectrum imidazole derivative whose antifungal activity is derived primarily from the inhibition of ergosterol biosynthesis, which is critical for cellular membrane integrity. It has fungicidal or fungistatic activity in vitro against a number of pathogenic fungi including the following dermatophytes, and yeasts: T. rubrum, T. mentagrophytes, T. tonsurans, T. violaceum, E. floccosum, M. canis, M. audouini, M. gypseum, C. albicans, and M. furfur.
Mechanism of actionOxiconazole inhibits ergosterol biosynthesis, which is required for cytoplasmic membrane integrity of fungi. It acts to destabilize the fungal cyctochrome P450 51 enzyme (also known as Lanosterol 14-alpha demethylase). This is vital in the cell membrance structure of the fungus. Its inhibition leads to cell lysis. Oxiconazole has also been shown in inhibit DNA synthesis and suppress intracellular concentrations of ATP. Like other imidazole antifungals, Oxiconazole can increase membrane permeability to zinc, augmenting its cytotoxicity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Lanosterol 14-alpha demethylaseProteinyes
inhibitor
YeastP10613 details
Lanosterol synthaseProteinyes
inhibitor
YeastQ04782 details
Related Articles
AbsorptionSystemic absorption of oxiconazole is low.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects incliude pruritus, burning, irritation, erythema, stinging and allergic contact dermatitis and folliculitis, fissuring, maceration rash and nodules.
Affected organisms
  • Fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe metabolism of Oxiconazole can be decreased when combined with Abiraterone.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Oxiconazole.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Amrinone.Approved
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Oxiconazole.Approved, Investigational
ArmodafinilThe metabolism of Oxiconazole can be decreased when combined with Armodafinil.Approved, Investigational
AzelnidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Barnidipine.Approved
BenidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Benidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Bepridil.Approved, Withdrawn
BortezomibThe metabolism of Oxiconazole can be decreased when combined with Bortezomib.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Oxiconazole.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Oxiconazole.Approved, Investigational
CaiThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Cai.Investigational
CarbamazepineThe metabolism of Oxiconazole can be increased when combined with Carbamazepine.Approved, Investigational
ChloramphenicolThe metabolism of Oxiconazole can be decreased when combined with Chloramphenicol.Approved, Vet Approved
CholecalciferolThe metabolism of Oxiconazole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Cilnidipine.Approved
CimetidineThe metabolism of Oxiconazole can be decreased when combined with Cimetidine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Cinnarizine.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Oxiconazole.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Oxiconazole can be decreased when combined with Citalopram.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Clevidipine.Approved
ClotrimazoleThe metabolism of Oxiconazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Oxiconazole.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Oxiconazole.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Oxiconazole can be decreased when it is combined with Dabrafenib.Approved
DarodipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Darodipine.Experimental
DelavirdineThe metabolism of Oxiconazole can be decreased when combined with Delavirdine.Approved
DidanosineDidanosine can cause a decrease in the absorption of Oxiconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Oxiconazole.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Oxiconazole.Approved
DotarizineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Dotarizine.Investigational
EfavirenzThe metabolism of Oxiconazole can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Efonidipine.Approved
EperisoneThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Eperisone.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Oxiconazole can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Oxiconazole can be decreased when combined with Esomeprazole.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Oxiconazole.Approved
FelodipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Fendiline.Withdrawn
FluconazoleThe metabolism of Oxiconazole can be decreased when combined with Fluconazole.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Flunarizine.Approved
FluoxetineThe metabolism of Oxiconazole can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Oxiconazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Oxiconazole can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Gallopamil.Investigational
GemfibrozilThe metabolism of Oxiconazole can be decreased when combined with Gemfibrozil.Approved
IndinavirThe metabolism of Oxiconazole can be decreased when combined with Indinavir.Approved
IsoniazidThe metabolism of Oxiconazole can be decreased when combined with Isoniazid.Approved
IsradipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Isradipine.Approved
KetoconazoleThe metabolism of Oxiconazole can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Lercanidipine.Approved, Investigational
LopinavirThe metabolism of Oxiconazole can be increased when combined with Lopinavir.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Oxiconazole.Approved
LuliconazoleThe serum concentration of Oxiconazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Oxiconazole can be decreased when it is combined with Lumacaftor.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Manidipine.Approved
MibefradilThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Mibefradil.Withdrawn
MoclobemideThe metabolism of Oxiconazole can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Oxiconazole can be decreased when combined with Modafinil.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Naftopidil.Investigational
NelfinavirThe metabolism of Oxiconazole can be decreased when combined with Nelfinavir.Approved
NicardipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nitrendipine.Approved
OmeprazoleThe metabolism of Oxiconazole can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
PantoprazoleThe metabolism of Oxiconazole can be decreased when combined with Pantoprazole.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Perhexiline.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Oxiconazole.Approved, Vet Approved
PimozideOxiconazole may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Oxiconazole.Approved, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Oxiconazole.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Oxiconazole.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Oxiconazole.Approved
RifampicinThe metabolism of Oxiconazole can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Oxiconazole.Approved
RisedronateThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Risedronate.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Oxiconazole.Approved
SertralineThe metabolism of Oxiconazole can be decreased when combined with Sertraline.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Oxiconazole.Approved
StiripentolThe metabolism of Oxiconazole can be decreased when combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Oxiconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Oxiconazole.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Oxiconazole.Approved, Investigational
TiclopidineThe metabolism of Oxiconazole can be decreased when combined with Ticlopidine.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Tolfenamic Acid.Approved
TopiramateThe metabolism of Oxiconazole can be decreased when combined with Topiramate.Approved
TranilastThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Oxiconazole can be decreased when combined with Tranylcypromine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Vinpocetine.Investigational
VoriconazoleThe metabolism of Oxiconazole can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Oxiconazole.Approved
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US4124767
General References
  1. Matsui H, Sakanashi Y, Oyama TM, Oyama Y, Yokota S, Ishida S, Okano Y, Oyama TB, Nishimura Y: Imidazole antifungals, but not triazole antifungals, increase membrane Zn2+ permeability in rat thymocytes Possible contribution to their cytotoxicity. Toxicology. 2008 Jun 27;248(2-3):142-50. doi: 10.1016/j.tox.2008.03.022. Epub 2008 Apr 7. [PubMed:18468760 ]
  2. Fromtling RA: Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988 Apr;1(2):187-217. [PubMed:3069196 ]
External Links
ATC CodesD01AC11G01AF17
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (33.7 KB)
MSDSDownload (24.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9903
Blood Brain Barrier+0.9699
Caco-2 permeable+0.5346
P-glycoprotein substrateNon-substrate0.6346
P-glycoprotein inhibitor INon-inhibitor0.7469
P-glycoprotein inhibitor IIInhibitor0.8492
Renal organic cation transporterInhibitor0.8361
CYP450 2C9 substrateNon-substrate0.8221
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6122
CYP450 1A2 substrateInhibitor0.793
CYP450 2C9 inhibitorInhibitor0.6532
CYP450 2D6 inhibitorNon-inhibitor0.6844
CYP450 2C19 inhibitorInhibitor0.8635
CYP450 3A4 inhibitorInhibitor0.6477
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8414
Ames testNon AMES toxic0.7381
CarcinogenicityNon-carcinogens0.7601
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5642 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6542
hERG inhibition (predictor II)Inhibitor0.507
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Altana inc
Packagers
Dosage forms
FormRouteStrength
CreamTopical10 mg/g
LotionTopical10 mg/mL
LotionTopical10 mg/g
LotionTopical30 mg/g
CreamTopical1 %
LotionTopical10 mg
Prices
Unit descriptionCostUnit
Oxistat 1% Cream 60 gm Tube157.99USD tube
Oxistat 1% Lotion 30ml Bottle93.13USD bottle
Oxistat 1% Cream 30 gm Tube90.31USD tube
Oxistat 1% Cream 15 gm Tube48.99USD tube
Oxistat 1% cream2.23USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00191 mg/mLALOGPS
logP5.28ALOGPS
logP5.84ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)6.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area39.41 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity105.95 m3·mol-1ChemAxon
Polarizability40.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassHalobenzenes
Direct ParentDichlorobenzenes
Alternative Parents
Substituents
  • 1,3-dichlorobenzene
  • Aryl chloride
  • Aryl halide
  • N-substituted imidazole
  • Azole
  • Heteroaromatic compound
  • Imidazole
  • Azacycle
  • Organoheterocyclic compound
  • Organohalogen compound
  • Organooxygen compound
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Organochloride
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
yes
Actions
inhibitor
General Function:
Sterol 14-demethylase activity
Specific Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name:
ERG11
Uniprot ID:
P10613
Molecular Weight:
60674.965 Da
References
  1. Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G: Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. [PubMed:16964330 ]
  2. Rossello A, Bertini S, Lapucci A, Macchia M, Martinelli A, Rapposelli S, Herreros E, Macchia B: Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J Med Chem. 2002 Oct 24;45(22):4903-12. [PubMed:12383016 ]
Kind
Protein
Organism
Yeast
Pharmacological action
yes
Actions
inhibitor
General Function:
Lanosterol synthase activity
Specific Function:
Catalyzes the cyclization of (S)-2,3 oxidosqualene to lanosterol, a reaction that forms the sterol nucleus.
Gene Name:
ERG7
Uniprot ID:
Q04782
Molecular Weight:
83713.975 Da
References
  1. Gebre-Hiwot A, Frommel D: The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosynthesis. J Antimicrob Chemother. 1993 Dec;32(6):837-42. [PubMed:8144423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P: Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48. Epub 2007 Nov 12. [PubMed:17998298 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Mahajan MK, Uttamsingh V, Daniels JS, Gan LS, LeDuc BW, Williams DA: In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug Metab Dispos. 2011 Apr;39(4):693-702. doi: 10.1124/dmd.110.036004. Epub 2010 Dec 21. [PubMed:21177487 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23